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Summary
Clinicopathological characteristics of small gastric carcinoma
have not been well deﬁned in Chinese patients. The aim of
this study was to investigate and compare small proximal
(PGC, n¼111) with distal (DGC, n¼ 202) gastric carcinoma
in 313 consecutive surgically resected small (2cm) gastric
carcinomas diagnosed with the WHO criteria. PGC patients
were signiﬁcantly older (average age 63 years versus 59 in
DGCs) with a male/female ratio of 3:1. Most tumours were
clustered along the lesser curvature (74% in PGCs and 65%
in DGCs). Compared to DGCs, PGCs showed a protruded
gross pattern signiﬁcantly more frequently and were signiﬁ-
cantly better differentiated with a signiﬁcantly wider histomor-
phological spectrum. Surprisingly, PGCs were composed of
signiﬁcantly fewer signet-ring cell carcinomas (1% versus
16% in DGCs) but were signiﬁcantly more deeply invasive,
compared to DGCs. Lymph node metastasis was detected in
23% overall, but was signiﬁcantly less frequent in PGCs
(16%) than in DGCs (26%) ( p<0.05). However, the differ-
ence in survival between the two groups was not statistically
signiﬁcant. Our results demonstrate that in Chinese patients,
PGCs display distinct clinicopathological characteristics,
compared to DGCs.
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INTRODUCTION
Gastric carcinoma is a heterogeneous disease. For instance, a
rising incidence of proximal gastric carcinoma (PGC) has been
reported almost worldwide, in contrast to a declining trend of
distal gastric carcinoma (DGC).1,2 Morphologically, PGCs
display a wider variety of uncommon histological subtypes
than the typical intestinal, diffuse, or mixed histology of
DGCs.3,4 Differences in molecular underpinning have also
been reported. For example, HER2 and Sirt1 genes are more
commonly expressed in PGCs than in DGCs.4,5 Gene expres-
sion arrays have shown variations in signal transduction path-
ways between PGC and DGC.6,7 Some authors provide
evidence for two aetiologies for PGCs: some are akin to
oesophageal adenocarcinoma (EAC) and related to gastroeso-
phageal reflux disease, whereas others are similar to DGC and
associated with Helicobacter pylori infection and atrophic
gastritis.8–11 Collectively, these observations favour PGC
and DGC being different diseases.
Despite recent advances in our understanding of PGC,
detailed clinicopathological studies of PGC in populations at
high risk for gastric carcinoma remain rare. Many previous
investigations include large, advanced neoplasms that obliter-
ate the landmark of the gastroesophageal junction (GEJ).3,12
This makes difficult a confident determination of the proximal
gastric origin of a tumour. Complexity also stems from the
controversial anatomical definition of the gastric cardia.13–15
However, the exact anatomical distribution of PGCs is import-
ant to define, since recent GEJ cancer staging guidelines, which
appear to be adequate for Western patients, have been shown to
be flawed for East Asian populations.16,17 Thus, the present
study was aimed to systematically investigate PGCs and to
compare their clinicopathological characteristics with DGCs in
a homogenous Chinese patient population with high risk for
gastric cancer but very low incidence of Barrett’s oesophagus
and EAC.18 We specifically restricted our study to small PGCs
measuring up to 2 cm in size to allow a better preservation of
histological landmarks of the GEJ in order to eliminate any
misclassification of gastric cancer as oesophageal in origin.
MATERIALS AND METHODS
Study group
All surgical pathology reports with a final diagnosis of gastric carcinoma from
January 2004 through December 2011 were mined from the electronic pathology
database of the Nanjing Drum Tower Hospital in China. Each report was
reviewed for demographics, tumour gross and microscopic characteristics,
and staging information. Inclusion criteria were: (1) surgically resected tumours
with lymph node dissection; and (2) tumour size up to 2 cm in maximum
dimension. Exclusion criteria included: (1) endoscopically resected tumours by
mucosal resection or submucosal dissection without lymph node dissection; (2)
tumour size larger than 2 cm; (3) no definitive invasion identified upon review of
all histology slides; (4) tumours with the epicentre located in the distal
oesophagus with a minor component of invasion into the proximal stomach;
(5) tumour in the gastric stump from a patient with prior partial gastrectomy; (6)
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the absence of tumour tissue blocks for recuts; (7) neoadjuvant therapy; and (8) a
distinct synchronous tumour detected within a minimal distance of 2 cm from the
main tumour.
Patient medical records including radiology and endoscopy reports, labora-
tory study results, and surgical operative notes were reviewed. In 30% of the
cases that were referred for surgery to the Nanjing Drum Tower Hospital but
with detailed pre-operative radiology and endoscopy performed at outside
institutions, the analysis was carried out principally on the local operative notes
and resection specimen pathology findings. Patients were followed up for
survival status through telephone or personal interview with the patient or
family members. Results were verified with the government citizen death
record. Patient consent for surgery and research was obtained in all cases
before surgical resection was carried out. The Medical Ethics Committee of the
Nanjing Drum Tower Hospital approved the study protocol.
Deﬁnition of carcinoma location, type, grade, and staging
All cases were divided into PGC and DGC groups, based on the location of
tumour’s epicentre. PGCs were defined as tumours with the epicentre located
within 3 cm below the GEJ.3,19 All other tumours distal to this 3 cm line were
grouped as DGCs.
Gastrectomy specimens were routinely processed.3,4 Partial gastrectomy for
PGCs was carried out by an abdominal trans-hiatal approach with at least 2 cm of
distal oesophagus resected. Tumour gross characteristics were obtained from
pathology reports, including size, shape, surface, colour, consistency, the
relationship to GEJ, resection margin, and the quality of adjacent gastric or
oesophageal mucosa. Gross and endoscopic digital images were reviewed, if
available. All tumours were macroscopically classified into five patterns, based
on previously published classification:20 (1) protruding with a broad base; (2)
elevated with a rough surface; (3) flat without elevation or depression; (4)
depressed with an eroded surface; and (5) excavated with an ulcerated centre and
a defined border.
All tumours were classified as adenocarcinoma, adenosquamous and muci-
nous carcinomas, carcinoma with lymphoid stroma, or poorly cohesive (includ-
ing signet-ring cell) carcinomas, using the WHO scheme.20 A well-
differentiated tumour exhibited well-formed papillae or tubules in over 95%
of the tumour, in contrast to a poorly differentiated carcinoma with irregular or
indiscernible glands in less than 50% of the tumour. In cases with morphological
features suspicious for neuroendocrine carcinoma, adenocarcinoma with pan-
creatic differentiation, and carcinoma with lymphoid stroma,3 appropriate
immunohistochemical (i.e., synaptophysin, chromogranin A, CD56, a1-chymo-
trypsin) and in situ hybridisation evaluations for Epstein–Barr virus (EBV) were
performed with standard protocols.
Lymphovascular and perineural invasion and the status of resection margins
were recorded. In cases with no carcinoma identified in routine sampling, the
entire gastric mucosa was submitted for histological examination.
All tumours were staged by the 7th edition of the American Joint Committee
on Cancer (AJCC) staging guidelines.21
Evaluation of adjacent uninvolved gastric mucosa
The presence or absence of chronic active gastritis, metaplasia (i.e., intestinal or
pancreatic), Helicobacter pylori infection (based on haematoxylin-eosin and
Giemsa stains), and atrophy (defined as either a reduced number of glands or
intestinal metaplasia) were recorded, based on the WHO definitions.20
Immunohistochemistry
Using conventional methods,3–5,22 immunohistochemistry was performed on
selected cases. The antibodies used were purchased from government-approved
vendors. Appropriate positive and negative controls were included in each
run.3–5,22 Two experienced pathologists, blinded to the patient’s clinical infor-
mation, reviewed each immunostain independently. The discrepancy between
readers was minimal, when present, and resolved by consensus.
In situ hybridisation for EBV-encoded small ribonucleic acid-1
EBV in situ hybridisation, as described previously with minimal modification,23
was carried out on tumour sections that were sequentially deparaffinised,
rehydrated through graded ethanol solutions in a decreasing order down to
water, then predigested with 0.4% peptidase, and hybridised overnight at 378C
with digoxigenin-labelled probes, based on the manufacturer’s instructions
(Zhongshan Jingqiao, China). The positive control consisted of Burkitt’s
lymphoma, and a normal lymph node served as the negative control. Both
controls were run in each batch to ensure validity.
Statistical analysis
Patient age, gender, Helicobacter pylori status, tumour location, gross pattern,
size, grade, type, stage, lymphovascular and perineural invasion, adjacent
uninvolved mucosa, and resection margin status were analysed and compared
between PGC and DGC groups with the Chi-square or Fisher’s exact test, when
appropriate. Survival rates were estimated by the Kaplan–Meier method with a
log rank test. The Cox regression analysis was used to identify risk factors for
overall survival. All analyses were carried out with the Statistical Package for
Social Sciences (Version 13; SPSS, USA). p values <0.05 were defined as
statistically significant.
RESULTS
Within the 8-year study period, 313 consecutive patients met
the inclusion criteria. The patients were divided into PGC
(n¼ 111, 35%) and DGC (n¼ 202, 65%) groups (Table 1).
The average number of tumour-bearing histology sections
reviewed was 3.5 (range 1–13) per case.
Demographics
Male gender was predominant in both PGC and DGC groups,
but the male/female patient ratio was significantly higher in
PGCs than in DGCs (3.1 versus 1.7, p< 0.05). The average age
of patients was also significantly older in PGCs (63 years) than
in DGCs (59 years, p< 0.05). There were no patients younger
than the age of 40 in the PGC group.
Tumour distribution and macroscopic characteristics
Overall, the majority (68%) of tumours arose along the lesser
curvature, mainly in two areas, the cardia and antrum (Table 1
and Fig. 1). The remaining tumours were scattered in the
corpus, pylorus, and the greater curvature.
Macroscopically (Table 1), excavated tumours were most
frequent (61%) overall, but significantly less so in PGCs
( p< 0.01). Protruding tumours (Fig. 2) were generally infre-
quent (7%), but more common in the PGC group than in the
DGC ( p< 0.0001). Elevated, flat, and depressed patterns were
less common in PGCs than in DGCs.
Table 1 Comparison of tumour gross characteristics
PGC (%) DGC (%)
Gross feature (n¼111) (n¼202) p
Size (cm)
AverageSD 1.6 0.47 1.5 0.5 NS
Range 0.3–2.0 0.3–2.0
Epicentre location
Gastroesophageal junction 10 (9) –
Fundus 5 (5) –
Lesser curvature 82 (74) 132 (65) NS
Greater curvature 6 (5) 16 (8) NS
Anterior/posterior wall 8 (7) 7 (4) NS
Antrum/anterior – 18 (9)
Incisura – 14 (7)
Corpus – 6 (3)
Pylorus – 9 (4)
Gross feature
Protruded 16 (15) 6 (3) 0.0001
Elevated 14 (13) 18 (9) NS
Flat 6 (5) 12 (6) NS
Depressed 18 (16) 27 (13) NS
Excavated 57 (51) 139 (69) 0.005
DGC, distal gastric carcinoma; NS, not signiﬁcant; PGC, proximal gastric
carcinoma; SD, standard deviation.
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Histopathology of small proximal gastric carcinomas
Compared to DGCs (Table 2), PGCs were significantly better
differentiated ( p< 0.001) and exhibited a wider histopatholo-
gical spectrum. While tubular adenocarcinoma was most com-
mon, pure and mixed mucinous carcinomas were predominant
among PGCs. Mixed squamous (Fig. 3A) and neuroendocrine
carcinomas were found only in PGCs. Papillary adenocarci-
noma (Fig. 3B) also occurred significantly more frequently in
PGCs (30%) than in DGCs (5%) ( p< 0.0001). A small pro-
portion (9%) of PGCs arose in mucous glands at the GEJ and
showed an expansile growth pattern with anastomosing gland-
ular architecture without evidence of columnar-lined oesopha-
gus with intestinal metaplasia (Fig. 3C). Micropapillary
(Fig. 3D), pure mucinous, pure neuroendocrine (Fig. 3E) car-
cinomas, and carcinoma with lymphoid stroma (confirmed with
the positive in situ hybridisation test for EBV, Fig. 3F) were
also more common in PGCs than in DGCs, but the differences
were not statistically significant. In contrast, pure and mixed
signet-ring cell carcinomas were significantly less common in
PGCs than in DGCs ( p< 0.001). Poorly cohesive carcinoma
(excluding signet-ring cell carcinoma) was also less common in
PGCs than in DGCs (Table 2). There were no significant
differences between the two groups in tumour size, lympho-
vascular and perineural invasion, and resection margin status.
Histopathology of adjacent gastric mucosa
The frequency of chronic active gastritis, intestinal metaplasia
and atrophy was similar in both groups (Table 2). Pancreatic
metaplasia was found only in PGCs. The frequency of Heli-
cobacter pylori infection was significantly lower in PGCs than
in DGCs ( p< 0.001).
Pathological staging
Partial gastrectomy (92%, 288/313) with D1 nodal dissection
(88%, 277/313) was carried out in the vast majority of cases
with an R0 resection rate of 91.7% (287/313) for the cohort.
The overall difference in the pT stage between PGC and DGC
groups was statistically significant (Table 3, p< 0.05). The
proportion of pT1 tumours was smaller in PGCs than in DGCs,
but the frequency of advanced tumours in pT3 and pT4 was
higher in PGCs than in DGCs (Table 3). The average number of
lymph nodes retrieved per case was 18.8 (17.1 in PGC and 19.7
in DGC). Lymph nodemetastasis was found in 23% of all cases,
but the frequency was significantly lower in PGCs (16%) than
in DGCs (26%) ( p<0.05). The only case with distant metas-
tasis was in the DGC group, in which a poorly differentiated,
mixed carcinoma with both signet-ring cell and pancreatic
acinar-like differentiations3,22 metastasised to the ovary in a
29-year-old woman. In the summary stage, the number of
patients staged as pIII was smaller in the PGC group than in
the DGC. There was no pIV case in the PGC group.
Patient survival
Sixty-five (21%) patients, 28 (25%) in the PGC group and 37
(17%) in the DGC, were lost to follow-up and excluded from
Fig. 1 Distribution of small (2 cm) gastric carcinomas. Note the two con-
centrated regions of tumours along the lesser curvature of the cardia and the
antrum separated with broken lines from the gastric corpus.
Esophagus
Proximal stomach
Fig. 2 Representative gross image of a proximal gastric carcinoma located
below the gastroesophageal junction and showing a broad-based protruding
tumour with a rough surface (arrow).
Table 2 Comparison of histopathology
PGC (%) DGC (%)
Microscopic characteristics (n¼ 111) (n¼ 202) p
Tumour differentiation
Well 22 (20) 17 (8.5) 0.0002
Moderately 45 (41) 59 (29)
Poorly 44 (39) 126 (63)
Histology type 0.0000
Adenocarcinoma
Tubular 50 (45) 106 (52)
Papillary 34 (30) 10 (5)
Mixed signet-ring cell 5 (5) 32 (16)
Mixed mucinous 5 (5) 2 (1)
Mixed squamous cell 2 (2) 0
Mixed neuroendocrine 2 (2) 0
Poorly cohesive adenocarcinoma* 3 (3) 18 (9)
Signet-ring cell carcinoma 1 (1) 32 (16)
Mucinous carcinoma 2 (2) 0
Carcinoma with lymphoid stroma 2 (2) 1 (0.5)
Neuroendocrine carcinoma 5 (2) 3 (1.5)
Perineural invasion 23 (21) 44 (21) NS
Lymphovascular invasion 22 (20) 45 (22) NS
Positive surgical resection margin 3 (3) 3 (1.5) NS
Adjacent gastric mucosa
Chronic active inﬂammation 107 (96) 199 (98.5) NS
Atrophic mucosa/intestinal metaplasia 97 (87) 176 (87) NS
Helicobacter pylori 59 (53) 150 (74.25) 0.0005
Pancreatic metaplasia 27 (24) 0 0
DGC, distal gastric carcinoma; NS, not signiﬁcant; PGC, proximal gastric
carcinoma; SD, standard deviation.
* Excluding signet-ring cell carcinoma.
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the survival analysis. At the last interview, 24 (10%) patients
had died, eight (7%) in the PGC group and 16 (8%) in the DGC.
Although the mean survival in PGCs [84.7 months, 95%
confidence interval (CI) 79.3–90.2] was shorter than that in
DGCs (94.4 months, 95% CI 89.6–99.1), the difference
between the two groups was not statistically significant
( p¼ 0.6) (Fig. 4). There was no significant difference in
survival between the two groups in stage-by-stage or year-
by-year comparisons. Multivariate analysis identified age 61
years [odds ratio (OR) 2.6; p< 0.05], pT3 (OR 13.3; p< 0.001),
and pT4 (OR 3.4; p< 0.05) tumours as significant independent
risk factors for worse overall survival.
DISCUSSION
In line with previous studies,3,6,24 our data show a predominant
distribution pattern of small gastric carcinoma along the lesser
curvature for both PGCs and DGCs. However, compared to
DGCs, PGCs demonstrate the following distinct clinicopatho-
logical characteristics: (1) elderly male predominance; (2)
more protruded and fewer excavated macroscopic growth
patterns; (3) better histological differentiation and a wider
morphological spectrum but fewer signet-ring cell carci-
nomas; (4) deeper invasion but fewer lymph node metastases;
and (5) lower frequency of Helicobacter pylori infection and
exclusive association with pancreatic metaplasia. All together,
we believe that these data, although yet insufficient to support
classifying PGC as a unique subtype of gastric cancer, under-
score the difference between two topographically distinct
gastric carcinomas.
In recent years, some investigators have proposed that PGCs
be considered as part of the distal EAC spectrum,12 based on the
assumption that PGC may originate from undetected short-
segment Barrett’s oesophagus. The results from the present
cohort and a previous study in the same Chinese patient
population have shown otherwise.3,18 In Chinese patients, distal
oesophageal Barrett’s oesophagus and EAC are rare,18 but PGC
is common and histologically heterogeneous.3 In contrast,
almost all distal EACs are pure adenocarcinomas of the intes-
tinal phenotype (Lauren classification).3,22 Furthermore, the
AJCC pathological staging rules for GEJ cancer have been
found deficient when applied to PGCs with oesophageal inva-
sion in both East Asian16,17 and European25 populations. The
discrepancymay result, at least partially, frommisclassification
A
C
E F
D
B
Fig. 3 Histological types of proximal gastric carcinoma. (A) Adenosquamous carcinoma showing both glandular and squamous (square area is enlarged in the inset)
components. (B) Pancreatic acinar-like adenocarcinoma features inﬁltrative small neoplastic acini with dense purplish, granular cytoplasm and immunoreactivity to a1-
chymotrypsin (inset: immunostain). (C) Proximal gastric carcinoma crossing the gastroesophageal junction demonstrates anastomosing (rectangular area is enlarged in
the inset), expansile growth patterns. Note the dilated oesophageal gland duct on the left. (D) Micropapillary adenocarcinoma. (E) Neuroendocrine carcinoma. Inset: the
immunoreactivity to synaptophysin is demonstrated. (F) Carcinoma with lymphoid stroma shows an expansile growth pattern and a sharply demarcated pushing border at
the invasion front. Inset: presence of Epstein–Barr virus in the nuclei (in situ hybridisation).
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of large PGCs as distal EACs in previous studies.12,26 Notably,
European investigators have described such misclassification
in a substantial number of cases, leading to a falsely increased
incidence of EACs.27
At present, neither the AJCC nor the Siewert classification28
reflect the cases examined in the Chinese population that we
studied, in which almost all small PGCs have an epicentre much
closer to the GEJ (<5 cm). As we have shown previously in
Chinese patients, most Siewert’s type II tumours (1 cm above
and 2 cm below the GEJ) are likely to represent proximal
gastric, but not distal oesophageal, tumours.3 In addition,
several Asian investigators have shown that Siewert’s type
III tumours (2–5 cm below the GEJ) present similar clinico-
pathological characteristics to DGCs.29–32 Consequently, given
the discrepancies and overlapping between these landmarks
(developed primarily with the data from Caucasian patients)
and the results obtained from Chinese patients, we chose to use
tumour epicentre at 3 cm below the GEJ as a new landmark for
PGC. Compared to DGCs, PGCs more often exhibit a macro-
scopically protruding pattern.3 PGCs are also in general better
differentiated and poorly cohesive carcinomas are unusual.24
However, PGCs are more deeply invasive, a characteristic
reported as an independent predictor of worse survival in
several Japanese series.24,33 Finally, pancreatic metaplasia
was frequently detected adjacent to PGCs, a finding not
described in association with distal EAC.3,12
Perhaps one of the most striking yet unexpected findings is a
high overall lymph node metastasis rate of 23%, which is much
higher than that reported in Japanese series evaluating early
small carcinomas (2 cm in size) with poor prognostic
indicators (ulcerative gross appearance and undifferentiated
carcinoma histology).34,35 In general, the prognosis of PGCs
is reported to be worse than that of DGCs.4,36–38 This is directly
related to the more advanced pT stage, as previously described
in Korean and Chinese patients.37,38 Furthermore, in this
cohort, advanced PGCs cases are rare (10% as pIII and none
as pIV), but patients show shorter survival, compared to DGCs,
although the difference in survival is not statistically signifi-
cant. This observation, in our opinion, suggests the need for a
large-scale survival study of PGC patients in order to better
evaluate their prognosis and predisposing factors.16,17,25
Given the similar frequency of chronic active gastritis with
intestinal metaplasia and atrophy in the mucosa surrounding
both PGCs and DGCs, Helicobacter pylori infection remains
the primary risk factor for gastric carcinomas in the Chinese
population. However, since the actual incidence of Helicobac-
ter pylori infection in PGCs is smaller, other risk factors may
play important roles in the development of PGCs. Those risk
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Fig. 4 Kaplan–Meier survival curves of patients with PGC or DGC tumours and staged as gastric carcinoma (AJCC 7). (A) There was no statistically signiﬁcant
difference between the PGC and DGC groups in overall survival outcomes. (B) Patients with PGCs were stratiﬁed according to different pathological stages; the
difference in survival stratiﬁcation was statistically signiﬁcant. (C) Patients with DGC demonstrated an excellent stage-by-stage, statistically signiﬁcant survival
stratiﬁcation difference ( p< 0.0001).
Table 3 Pathological (pTMN) staging
Pathological
staging (pTNM)
Proximal
(PGC, %)
Distal
(DGC, %)
p (PGC vs
DGC)
Total cases 111 202
pT 0.0343
1 61 (55) 129 (64)
1A 30 (27) 82 (40.5)
1B 31 (28) 47 (23)
2 26 (23) 38 (19)
3 11 (10) 14 (7)
4 13 (12) 21 (10)
4A 6 (6) 3 (1.5)
4B 7 (6.5) 18 (9)
pN 0.048
0 93 (84) 149 (74)
1 10 (9) 26 (13)
2 6 (6) 15 (7.5)
3a 2 (2) 12 (6)
pM NS
0 111 (100) 201 (100)
1 0 1 (0.5)
Summary stage NS
I 84 (76) 140 (70)
IA 56 (50) 109 (54)
IB 28 (25) 31 (15)
II 16 (14) 35 (17)
IIA 10 (9) 27 (13.5)
IIB 6 (6) 8 (4.5)
III 11 (10) 26 (13)
IIIA 1 (1) 6 (3)
IIIB 6 (6) 13 (6.5)
IIIC 4 (4) 7 (4)
IV 0 1 (0.5)
DGC, distal gastric carcinoma; NS, not signiﬁcant; PGC, proximal gastric
carcinoma.
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factors may include tobacco abuse (epidemic in China) and
obesity. Of note, two recent meta-analyses emphasise the
relationship between increased body mass index and the risk
of gastric cancer development, especially in the proximal
stomach.39,40
Finally, using comparative genomic hybridisation, Japanese
researchers have described statistically significant chromoso-
mal gains and losses in 35 PGCs, compared to 67 DGCs.41 In
PGCs, the most common deletion is on chromosome 18q,
where the tumour suppressor smad gene (a key regulator of
the transforming growth factor-b signalling pathway) is
located.42 Recently, Canadian researchers have reported, in
an abstract form, the presence of mutational differences
between gastric cardia (PGC) and non-cardia (DGC) carci-
nomas.7 Their findings are confirmed by the most recent data
on comprehensive molecular characterisation of gastric carci-
noma,43 supporting the concept of pathobiological diversity
between PGCs and DGCs.7
The major limitation of this retrospective study includes
inherent deficiency in data uniformity, such as collection of
tumour gross images, standardisation of endoscopic investi-
gation with biopsies, and completion of survival investigation.
A further limitation is the lack of results on adjuvant therapy,
which could confound the survival data. Although such vari-
ables are difficult to control, the main findings of the study are
unlikely to be adversely affected, because of the large sample
size, strict exclusion criteria, and detailed histopathological
investigations.
In summary, based on the evidence acquired from present
and previous studies,3,6,7,17,25 PGC can be characterised as an
elderly male predominant, heterogeneous gastric carcinoma,
frequently presenting with better differentiation, deeper
penetration, and fewer nodal metastases, in comparison to
DGC. Altogether, these results detail striking clinicopatholo-
gical differences between PGCs and DGCs in the Chinese
population. However, the data are yet insufficient to support
classifying PGC as a unique subtype of gastric cancer.
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